U.S. Department of Defense Picks New QuikClot(R) Combat Gauze(TM) as First-Line Hemostatic Treatment for All Military Services

Thursday, May 15, 2008 General News
Email Print This Page Comment
WALLINGFORD, Conn., May 14 Z-Medica Corporation (Z-Medica),a medical products company focused on innovative blood clottingnano-technologies, announced that the United States Department of Defense hasselected the company's newest hemostatic product, QuikClot(R) Combat Gauze(TM)brand, for all military services as the first-line hemostatic treatment forlife-threatening hemorrhage that is not amenable to tourniquet placement.Bleeding is the number one cause of death for soldiers injured in battle andQuikClot(R) products offer the most effective solution to severe blood lossoutside the operating room setting. They have been proven in battlefield useand, with more than one million units deployed, are the leading hemostaticagents in the field.

The Committee on Tactical Combat Casualty Care (CoTCCC) made the decisionto recommend QuikClot(R) Combat Gauze(TM) after reviewing test reports on anumber of hemostatic products. QuikClot(R) Combat Gauze(TM) was the only oneof these products tested by both the Naval Medical Research Center and the U.S.Army Institute for Surgical Research. In addition to test efficacy, thecommittee sited a number of other factors in according QuikClot(R) CombatGauze(TM) the number one position:

"Z-Medica's approach to product innovation has always been to listen tothe voice of our customer and to focus our research & development efforts ondelivering life-saving products that meet their needs," said Z-Medica CEORaymond J. Huey. "With QuikClot(R) Combat Gauze(TM) we have provided a productthat is virtually 100% effective in a very intuitive format that can beapplied quickly and simply by anyone."

QuikClot(R) Combat Gauze(TM) combines surgical gauze with a proprietaryinorganic material that stops arterial and venous bleeding in seconds -- evenmore rapidly in this format than earlier Z-Medica products. Based on adifferent mineral than zeolite-based QuikClot(R) products, it generates noheat. It shares the benefit of being inert and non-allergenic. QuikClot(R)Combat Gauze(TM) comes in rolls four yards long by three inches wide.

In addition to the military testing, the new product was tested inpre-clinical trials at the University of California, Santa Barbara, theUniversity of Massachusetts Medical School and at various field facilities. Ithas 510(k) clearance from the U.S. Food & Drug Administration. The UnitedStates Department of Defense has awarded Z-Medica a $3.2 million grant forlarge-scale testing of the product on penetrating wounds. These multi-centerclinical trials will take place during 2008.

Earlier QuikClot(R) products are in use by all branches of the U.S.Military, by first responders and security agencies across the U.S. and in 36countries worldwide, with more than a million units in distribution. Z-Medicarecently launched its first products for consumers.

About Z-Medica

Founded in April 2002, Z-Medica Corporation is a medical products companyfocused on innovative blood clotting technologies -- hemostatic solutions thatsave lives. QuikClot(R) was developed in cooperation with the Office of NavalResearch (ONR), the U.S. Marine Corps Warfighting Laboratory, the U.S. MarineCorps Systems Command and university hospitals. It represents the first andmost effective solution to severe blood loss outside the operating roomsetting. Z-Medica serves several global vertical markets, including military,first responder, homeland and private security. The U.S. Department ofHomeland Security's Office of Grants & Training added 'hemostatic agent' toits 2006 Authorized Equipment List (AEL), qualifying QuikClot(R) for purchaseusing grant dollars, subject to each State's administrative agency's approval.And, in 2007, the National Tactical Officers Association gave the company andits new products their coveted official seal of "NTOA member tested andapproved". In addition to QuikClot(R) Combat Gauze(TM), the


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook